CCM
SRPT icon

Copernicus Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Copernicus Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-30,000
Closed -$4.56M – 18
2019
Q2 		$4.56M Buy
+30,000
New +$3.65M 4.06% 11

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Copernicus Capital Management's SRPT Position: Q3 2019 in Review

Copernicus Capital Management sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 30,000 shares — an estimated $4.56M sold.

Copernicus Capital Management first reported a position in SRPT in Q2 2019 and held it in 1 quarter. The position peaked at $4.56M in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • Copernicus Capital Management reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Copernicus Capital Management sold 30,000 Sarepta Therapeutics shares in Q3 2019, an estimated $4.56M.
  • Copernicus Capital Management first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 1 quarter.
  • Copernicus Capital Management's Sarepta Therapeutics position peaked at $4.56M in Q2 2019.
  • 340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Copernicus Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.